Show simple item record  

dc.contributor.authorElwood, J. Marken_NZ
dc.contributor.authorTin Tin, Sandaren_NZ
dc.contributor.authorKuper-Hommel, Marionen_NZ
dc.contributor.authorLawrenson, Rossen_NZ
dc.contributor.authorCampbell, Ianen_NZ
dc.date.accessioned2018-06-11T00:32:38Z
dc.date.available2018-01-15en_NZ
dc.date.available2018-06-11T00:32:38Z
dc.date.issued2018en_NZ
dc.identifier.citationElwood, J. M., Tin Tin, S., Kuper-Hommel, M., Lawrenson, R., & Campbell, I. (2018). Obesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort study. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-017-3971-4en
dc.identifier.urihttps://hdl.handle.net/10289/11887
dc.description.abstractBackground: Obesity has been reported as an adverse prognostic factor in breast cancer, but inconsistently, and under-treatment with chemotherapy may occur. We provide the first assessment of obesity and breast cancer outcomes in a population-based, multi-ethnic cohort of New Zealand patients treated with chemotherapy. Methods: All 3536 women diagnosed with invasive breast cancer in the Waikato region of New Zealand from 2000-2014 were registered and followed until last follow-up in specialist or primary care, death or Dec 2014; median follow-up 4.1 years. For the 1049 patients receiving chemotherapy, mortality from breast cancer, other causes, and all causes, and rates of loco-regional and of distant recurrence, were assessed by body mass index (BMI), recorded after diagnosis, adjusting for other clinico-pathological and demographic factors by Cox regression. Results: BMI was known for 98% (n=1049); 33% were overweight (BMI 25-29.9), 21% were obese (BMI 30-34.9), and 14% were very obese (BMI 35+). There were no significant associations between obesity and survival, after adjustment for demographic and clinical factors (hazard ratios, HR, for very obese compared to BMI 21-24, for breast cancer deaths 0.96 (0.56-1.67), and for all deaths 1.03 (0.63-1.67), respectively, and only small non-significant associations for loco-regional or metastatic recurrence rates (HR 1.17 and 1.33 respectively). Subgroup analyses by age, menopausal status, ethnicity, stage, post-surgical radiotherapy, mode of diagnosis, type of surgery, and receptor status, showed no associations. No associations were seen with BMI as a continuous variable. The results in all patients irrespective of treatment but with recorded BMI data (n=2296) showed similar results. Conclusions: In this population, obesity assessed post-diagnosis had no effect on survival or recurrence, based on 1049 patients with chemotherapy treatment with follow-up up to 14 years.
dc.format.mimetypeapplication/pdf
dc.language.isoen
dc.publisherBMC
dc.rights© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.subjectBreast cancer
dc.subjectObesity
dc.subjectBody-mass index
dc.subjectSurvival
dc.subjectRecurrence
dc.titleObesity and breast cancer outcomes in chemotherapy patients in New Zealand - a population-based cohort studyen_NZ
dc.typeJournal Article
dc.identifier.doi10.1186/s12885-017-3971-4en_NZ
dc.relation.isPartOfBMC Canceren_NZ
pubs.elements-id217786
pubs.issue1en_NZ
pubs.publication-statusPublisheden_NZ
pubs.volume18en_NZ
dc.identifier.eissn1471-2407en_NZ


Files in this item

This item appears in the following Collection(s)

Show simple item record